Literature DB >> 9495864

Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.

H Sasabe1, A Tsuji, Y Sugiyama.   

Abstract

Grepafloxacin (GPFX) has a comparatively greater hepatobiliary transport than other quinolone antibiotics. The biliary excretion mechanism of GPFX was investigated in a series of in vivo and in vitro studies with Sprague-Dawley rats and the mutant strain Eisai-hyperbilirubinemia rats (EHBR), which have a hereditary defect in their bile canalicular multispecific organic anion transport system (cMOAT). The biliary excretion of the parent drug in EHBR was 38% of that in normal rats, whereas the 3-glucuronide, a main metabolite of GPFX, was scarcely excreted into the bile in EHBR. To clarify the biliary excretion mechanism of GPFX, studies of uptake by bile canalicular membrane vesicle (CMV) were performed. ATP dependence was observed in the uptake of GPFX by CMV, although the extent was not very marked, whereas no ATP-dependent uptake was observed by CMV prepared from EHBR. An inhibition study of the ATP-dependent uptake of the glutathione conjugate, 2,4-dinitrophenyl-S-glutathione (DNP-SG), a typical substrate for cMOAT, was performed in order to differentiate among the affinities of six quinolone antibiotics for this transporter. All quinolone antibiotics inhibited the ATP-dependent uptake of DNP-SG with different half-inhibition concentrations (IC50), and GPFX had the lowest IC50 value. The uptake of GPFX-glucuronide by CMV from normal rats showed a marked ATP dependence, whereas there was little ATP-dependent uptake in EHBR. The K(m) value (7.2 microM) for the higher-affinity component of the glucuronide uptake was comparable to the Ki value (9.2 microM) of the glucuronide in terms of inhibition of the ATP-dependent uptake of DNP-SG, which indicates that DNP-SG and the glucuronide may share the same transporter, cMOAT. The Ki value of the glucuronide observed in this inhibition was less than 1/200 that of the parent, which suggests that the glucuronide had a much higher affinity than the parent drug. These results lead us to conclude that at least a part of the GPFX transport and a major part of its glucuronide transport across the bile canalicular membrane are by a primary active transport mechanism mediated by cMOAT.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9495864

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Environmental metabolites of fluoroquinolones: synthesis, fractionation and toxicological assessment of some biologically active metabolites of ciprofloxacin.

Authors:  Gareth Lewis; Albert Juhasz; Euan Smith
Journal:  Environ Sci Pollut Res Int       Date:  2012-02-04       Impact factor: 4.223

2.  Detection of antibacterial-like activity on a silica surface: fluoroquinolones and their environmental metabolites.

Authors:  Gareth Lewis; Albert Juhasz; Euan Smith
Journal:  Environ Sci Pollut Res Int       Date:  2012-02-05       Impact factor: 4.223

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.

Authors:  Kazumasa Naruhashi; Ikumi Tamai; Natsuko Inoue; Hiromi Muraoka; Yoshimichi Sai; Nagao Suzuki; Akira Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome.

Authors:  S Toh; M Wada; T Uchiumi; A Inokuchi; Y Makino; Y Horie; Y Adachi; S Sakisaka; M Kuwano
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

6.  Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats.

Authors:  Ying Lan Zhao; Xiao Bo Cen; Masafumi Ito; Keiko Yokoyama; Kenji Takagi; Kiyoyuki Kitaichi; Masayuki Nadai; Michio Ohta; Kenzo Takagi; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Multidrug resistance-associated protein 1 functions as an efflux pump of xenobiotics in the skin.

Authors:  Qing Li; Yukio Kato; Yoshimichi Sai; Teruko Imai; Akira Tsuji
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

Review 8.  The apical conjugate efflux pump ABCC2 (MRP2).

Authors:  Anne T Nies; Dietrich Keppler
Journal:  Pflugers Arch       Date:  2006-07-18       Impact factor: 3.657

9.  Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells.

Authors:  Salvatore Cisternino; Christophe Rousselle; Aurelio Lorico; Germana Rappa; Jean-Michel Scherrmann
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

10.  Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter.

Authors:  Yasuo Uchida; Junichi Kamiie; Sumio Ohtsuki; Tetsuya Terasaki
Journal:  Pharm Res       Date:  2007-10-16       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.